Literature DB >> 30188757

Sphingosine-1-phosphate (S1P) induces potent anti-inflammatory effects in vitro and in vivo by S1P receptor 4-mediated suppression of 5-lipoxygenase activity.

Jasmin Fettel1, Benjamin Kühn1, Nathalie A Guillen1, Duran Sürün2, Marcus Peters3, Rebekka Bauer1, Carlo Angioni4, Gerd Geisslinger4, Frank Schnütgen2, Dagmar Meyer Zu Heringdorf5, Oliver Werz6, Patrick Meybohm7, Kai Zacharowski7, Dieter Steinhilber1, Jessica Roos7, Thorsten J Maier7.   

Abstract

Sphingosine-1-phosphate (S1P) is involved in the regulation of important cellular processes, including immune-cell trafficking and proliferation. Altered S1P signaling is strongly associated with inflammation, cancer progression, and atherosclerosis; however, the mechanisms underlying its pathophysiologic effects are only partially understood. This study evaluated the effects of S1P in vitro and in vivo on the biosynthesis of leukotrienes (LTs), which form a class of lipid mediators involved in the pathogenesis of inflammatory diseases. Here, we report for the first time that S1P potently suppresses LT biosynthesis in Ca2+-ionophore-stimulated intact human neutrophils. S1P treatment resulted in intracellular Ca2+ mobilization, perinuclear translocation, and finally irreversible suicide inactivation of the LT biosynthesis key enzyme 5-lipoxygenase (5-LO). Agonist studies and S1P receptor mRNA expression analysis provided evidence for a S1P receptor 4-mediated effect, which was confirmed by a functional knockout of S1P4 in HL60 cells. Systemic administration of S1P in wild-type mice decreased both macrophage and neutrophil migration in the lungs in response to LPS and significantly attenuated 5-LO product formation, whereas these effects were abrogated in 5-LO or S1P4 knockout mice. In summary, targeting the 5-LO pathway is an important mechanism to explain S1P-mediated pathophysiologic effects. Furthermore, agonism at S1P4 represents a novel effective strategy in pharmacotherapy of inflammation.-Fettel, J., Kühn, B., Guillen, N. A., Sürün, D., Peters, M., Bauer, R., Angioni, C., Geisslinger, G., Schnütgen, F., Meyer zu Heringdorf, D., Werz, O., Meybohm, P., Zacharowski, K., Steinhilber, D., Roos, J., Maier, T. J. Sphingosine-1-phosphate (S1P) induces potent anti-inflammatory effects in vitro and in vivo by S1P receptor 4-mediated suppression of 5-lipoxygenase activity.

Entities:  

Keywords:  calcium; inactivation of 5-LO; inflammation; leukotriene formation; lipid mediators

Mesh:

Substances:

Year:  2018        PMID: 30188757     DOI: 10.1096/fj.201800221R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  12 in total

1.  MRSA-induced endothelial permeability and acute lung injury are attenuated by FTY720 S-phosphonate.

Authors:  Lichun Wang; Eleftheria Letsiou; Huashan Wang; Patrick Belvitch; Lucille N Meliton; Mary E Brown; Mounica Bandela; Jiwang Chen; Joe G N Garcia; Steven M Dudek
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-12-08       Impact factor: 5.464

Review 2.  Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis - a unique therapeutic target in inflammatory bowel disease.

Authors:  Jie Wang; Idan Goren; Bo Yang; Sinan Lin; Jiannan Li; Michael Elias; Claudio Fiocchi; Florian Rieder
Journal:  Aliment Pharmacol Ther       Date:  2021-12-21       Impact factor: 8.171

3.  Saliva metabolomic profile of COVID-19 patients associates with disease severity.

Authors:  Mohammad H Semreen; Rabih Halwani; Narjes Saheb Sharif-Askari; Nelson Cruz Soares; Hajer A Mohamed; Fatemeh Saheb Sharif-Askari; Hawra Ali Hussain Alsayed; Hamza Al-Hroub; Laila Salameh; Rufaida Satti Osman; Bassam Mahboub; Qutayba Hamid
Journal:  Metabolomics       Date:  2022-10-22       Impact factor: 4.747

Review 4.  Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities.

Authors:  Victoria A Blaho
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

5.  Trends in the Use of Sphingosine 1 Phosphate in Age-Related Diseases: A Scientometric Research Study (1992-2020).

Authors:  Qiong He; Gaofeng Ding; Mengyuan Zhang; Peng Nie; Jing Yang; Dong Liang; Jiaqi Bo; Yi Zhang; Yunfeng Liu
Journal:  J Diabetes Res       Date:  2021-02-25       Impact factor: 4.011

Review 6.  Potential therapeutic targets for atherosclerosis in sphingolipid metabolism.

Authors:  Zemou Yu; Qing Peng; Yining Huang
Journal:  Clin Sci (Lond)       Date:  2019-03-19       Impact factor: 6.124

7.  Alignment independent 3D-QSAR studies and molecular dynamics simulations for the identification of potent and selective S1P1 receptor agonists.

Authors:  Ali Akbar Alizadeh; Behzad Jafari; Siavoush Dastmalchi
Journal:  J Mol Graph Model       Date:  2019-09-29       Impact factor: 2.518

Review 8.  A Comprehensive Review: Sphingolipid Metabolism and Implications of Disruption in Sphingolipid Homeostasis.

Authors:  Brianna M Quinville; Natalie M Deschenes; Alex E Ryckman; Jagdeep S Walia
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

9.  Validated LC-MS/MS method of Sphingosine 1-phosphate quantification in human serum for evaluation of response to radiotherapy in lung cancer.

Authors:  Xiaohui Tang; Haisheng Chen; Guanxuan Chen; Cunxian Duan; Qing Fan; Hui Li; Yanhong Wang; Zhijun Li; Wenna Shi; Yuguo Liu
Journal:  Thorac Cancer       Date:  2020-03-31       Impact factor: 3.500

10.  Sphingosine 1-phosphate Stimulates Insulin Secretion and Improves Cell Survival by Blocking Voltage-dependent K+ Channels in β Cells.

Authors:  Zhihong Liu; Huanhuan Yang; Linping Zhi; Huan Xue; Zhihong Lu; Yanli Zhao; Lijuan Cui; Tao Liu; Shouan Ren; Peifeng He; Yunfeng Liu; Yi Zhang
Journal:  Front Pharmacol       Date:  2021-07-12       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.